ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) OPTIONS

The present work examined the potential of employing ARV-825 and ABBV-744 to boost the effectiveness of tamoxifen or fulvestrant as well as palbociclib. ARV-825 was effective in each p53 wild-form (WT) breast tumor cells As well as in cells missing purposeful p53 possibly alone or in combination with tamoxifen, whilst the effectiveness of ABBV-744